NCT02341625: A trial that was reported late by Bristol-Myers Squibb
This trial has reported, although it was 776 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02341625 |
|---|---|
| Title | A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | June 19, 2015 |
| Completion date | Feb. 25, 2019 |
| Required reporting date | Feb. 25, 2020, midnight |
| Actual reporting date | April 11, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 776 |